Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 124.41
- Piotroski Score 5.00
- Grade Overweight
- Symbol (SPRY)
- Company ARS Pharmaceuticals, Inc.
- Price $14.45
- Changes Percentage (-0.1%)
- Change -$0.02
- Day Low $14.01
- Day High $14.56
- Year High $16.50
ARS Pharmaceuticals, Inc. develops ARS-1, a novel intranasal epinephrine spray with absorption technology for patients and their families at-risk of severe allergic reactions to food, medications, and insect bites. Its product includes Neffy, a low-dose intranasal epinephrine nasal spray. The company was incorporated in 2015 and is based in San Diego, California.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/06/2024
- Fiscal Year End N/A
- Average Stock Price Target $22.00
- High Stock Price Target $30.00
- Low Stock Price Target $18.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$0.52
- Trailing P/E Ratio -16.94
- Forward P/E Ratio -16.94
- P/E Growth -16.94
- Net Income $-54,365,000
Income Statement
Quarterly
Annual
Latest News of SPRY
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
ARS Pharmaceuticals (SPRY): A Bull Case Theory
ARS Pharmaceuticals presents a strong investment opportunity with its FDA-approved needle-free epinephrine nasal spray, Neffy, aiming to disrupt the EpiPen market. With potential for significant marke...
By Yahoo! Finance | 3 weeks ago -
ARS Pharmaceuticals Inc (SPRY) CFO Kathleen Scott Sells 12,500 Shares
On August 20, 2024, Kathleen Scott, CFO of ARS Pharmaceuticals Inc, sold 12,500 shares at $16/share. The company focuses on developing health solutions. With a market cap of $1.299 billion, investors ...
By Yahoo! Finance | 1 month ago -
Insider Sale: COO Brian Dorsey Sells 30,000 Shares of ARS Pharmaceuticals Inc (SPRY)
Brian Dorsey, COO of ARS Pharmaceuticals Inc (NASDAQ:SPRY), sold 30,000 shares, now owning 6,024 shares. The company focuses on developing innovative drug products, primarily epinephrine for severe al...
By Yahoo! Finance | 1 month ago
